Literature DB >> 977992

Role of maternal antibody in pneumonia and bronchiolitis due to respiratory syncytial virus.

C L Lamprecht, H E Krause, M A Mufson.   

Abstract

Fifteen infants with pneumonia caused by respiratory syncytial virus (RSV) and 19 infants with bronchiolitis caused by RSV were studied for the influence of homologous, circulating neutralizing antibody on the severity of their illness. All infants were under nine months of age. Although maternal neutralizing antibody did not prevent infection with RSV and illness, the severity of pneumonia caused by RSV was inversely related to the level of neutralizing antibody. The severity of bronchiolitis caused by RSV was unrelated to maternal antibody levels. Chest roentgenograms showed pneumonia to be slightly more severe than bronchiolitis. Neither the severity of illness nor the presence of maternal neutralizing antibody was related to the development of complement-fixing antibody.

Entities:  

Mesh：

Substances：

Year:  1976        PMID： 977992     DOI： 10.1093/infdis/134.3.211

Source DB:  PubMed          Journal:  J Infect Dis        ISSN： 0022-1899            Impact factor:   5.226


  49 in total

Review 1.  Mammary gland immunity and mastitis susceptibility.

Authors:  Lorraine M Sordillo; Katie L Streicher
Journal:  J Mammary Gland Biol Neoplasia       Date:  2002-04       Impact factor: 2.673

Review 2.  Neonatal innate immunity to infectious agents.

Authors:  László Maródi
Journal:  Infect Immun       Date:  2006-04       Impact factor: 3.441

Review 3.  Immunity to human and bovine respiratory syncytial virus.

Authors:  T G Kimman; F Westenbrink
Journal:  Arch Virol       Date:  1990       Impact factor: 2.574

4.  Resistance to human respiratory syncytial virus (RSV) infection induced by immunization of cotton rats with a recombinant vaccinia virus expressing the RSV G glycoprotein.

Authors:  N Elango; G A Prince; B R Murphy; S Venkatesan; R M Chanock; B Moss
Journal:  Proc Natl Acad Sci U S A       Date:  1986-03       Impact factor: 11.205

5.  Replication-competent or attenuated, nonpropagating vesicular stomatitis viruses expressing respiratory syncytial virus (RSV) antigens protect mice against RSV challenge.

Authors:  J S Kahn; A Roberts; C Weibel; L Buonocore; J K Rose
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

Review 6.  Hyperimmune globulins in prevention and treatment of respiratory syncytial virus infections.

Authors:  V G Hemming; G A Prince; J R Groothuis; G R Siber
Journal:  Clin Microbiol Rev       Date:  1995-01       Impact factor: 26.132

7.  Prophylaxis with a respiratory syncytial virus (RSV) anti-G protein monoclonal antibody shifts the adaptive immune response to RSV rA2-line19F infection from Th2 to Th1 in BALB/c mice.

Authors:  Seyhan Boyoglu-Barnum; Tatiana Chirkova; Sean O Todd; Thomas R Barnum; Kelsey A Gaston; Patricia Jorquera; Lia M Haynes; Ralph A Tripp; Martin L Moore; Larry J Anderson
Journal:  J Virol       Date:  2014-07-02       Impact factor: 5.103

8.  Controlled trial to evaluate protection of high-risk infants against respiratory syncytial virus disease by using standard intravenous immune globulin.

Authors:  H C Meissner; D R Fulton; J R Groothuis; R L Geggel; G R Marx; V G Hemming; T Hougen; D R Snydman
Journal:  Antimicrob Agents Chemother       Date:  1993-08       Impact factor: 5.191

9.  Subgroup characteristics of respiratory syncytial virus strains recovered from children with two consecutive infections.

Authors:  M A Mufson; R B Belshe; C Orvell; E Norrby
Journal:  J Clin Microbiol       Date:  1987-08       Impact factor: 5.948

10.  The level and duration of RSV-specific maternal IgG in infants in Kilifi Kenya.

Authors:  Rachel Ochola; Charles Sande; Gregory Fegan; Paul D Scott; Graham F Medley; Patricia A Cane; D James Nokes
Journal:  PLoS One       Date:  2009-12-02       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.